Log in
NASDAQ:PULM

Pulmatrix Stock Forecast, Price & News

$1.12
+0.08 (+7.69 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.99
Now: $1.12▼
$1.13
50-Day Range
$1.04
MA: $1.15▼
$1.27
52-Week Range
$0.72
Now: $1.12▼
$2.06
Volume454,232 shs
Average Volume1.01 million shs
Market Capitalization$38.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. Pulmatrix, Inc. has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; definitive agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a research collaboration with Nocion Therapeutics Inc. to explore technologies that enable and improve inhaled drug delivery. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Read More
Pulmatrix logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.28 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
Previous Symbol
CUSIPN/A
CIK1574235
Webwww.pulmatrix.com
Phone781-357-2333
Employees22

Debt

Debt-to-Equity RatioN/A
Current Ratio1.99
Quick Ratio1.99

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.91 million
Price / Sales4.87
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.55 per share
Price / Book2.04

Profitability

EPS (Most Recent Fiscal Year)($0.80)
Net Income$-20,600,000.00
Net Margins-143.83%
Return on Equity-115.55%
Return on Assets-39.88%

Miscellaneous

Outstanding Shares34,407,000
Market Cap$38.54 million
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$1.12
+0.08 (+7.69 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

How has Pulmatrix's stock been impacted by COVID-19?

Pulmatrix's stock was trading at $1.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PULM shares have decreased by 18.8% and is now trading at $1.12.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Pulmatrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pulmatrix.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Pulmatrix.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) posted its earnings results on Friday, August, 7th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.33. The biotechnology company earned $3.50 million during the quarter. Pulmatrix had a negative return on equity of 115.55% and a negative net margin of 143.83%.
View Pulmatrix's earnings history.

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Pulmatrix shares reverse split on the morning of Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PULM?

1 analysts have issued twelve-month price objectives for Pulmatrix's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Pulmatrix's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 792.9% from the stock's current price.
View analysts' price targets for Pulmatrix.

Are investors shorting Pulmatrix?

Pulmatrix saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 222,100 shares, an increase of 87.7% from the September 30th total of 118,300 shares. Based on an average trading volume of 556,500 shares, the short-interest ratio is currently 0.4 days.
View Pulmatrix's Short Interest.

Who are some of Pulmatrix's key competitors?

Some companies that are related to Pulmatrix include NuCana (NCNA), Actinium Pharmaceuticals (ATNM), Mustang Bio (MBIO), Enlivex Therapeutics (ENLV), OptiNose (OPTN), Theratechnologies (THTX), Theratechnologies (THERF), Galectin Therapeutics (GALT), Ampio Pharmaceuticals (AMPE), Sierra Oncology (SRRA), BIOFRONTERA AG/ADR (BFRA), Milestone Pharmaceuticals (MIST), Enochian Biosciences (ENOB), AVEO Pharmaceuticals (AVEO) and BELLUS Health (BLU).
View all competitors.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the following people:
  • Mr. Teofilo David Raad, Pres, CEO & Director (Age 49, Pay $599.69k)
  • Ms. Michelle S. Siegert, VP of Fin. and Principal Financial & Accounting Officer
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 71)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 59)
  • Dr. Alexander M. Klibanov, Founder (Age 70)

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include WINTON GROUP Ltd (0.11%).
View institutional ownership trends for Pulmatrix.

Which institutional investors are buying Pulmatrix stock?

PULM stock was purchased by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd.
View insider buying and selling activity for Pulmatrix.

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $1.12.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $38.54 million and generates $7.91 million in revenue each year. The biotechnology company earns $-20,600,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.

What is Pulmatrix's official website?

The official website for Pulmatrix is www.pulmatrix.com.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.